Safety and Pharmacokinetics of TAF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender Women

Phase 3, randomised, open-label trial of tenofovir alafenamide and emtricitabine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by University of Washington. Primary endpoints: Frequency of Adverse Events at 10 weeks, Concentrations of Tenofovir Disphosphate (TFV-DP) and Emtricitabine Triphosphate (FTC-TP) Measured at Ten Weeks in Dried Blood Spots (DBS) at 10 weeks and 2 more. Started Apr 2023; status: completed.